Paradigm Health Implements New Clinical Trial Solution to Support Observational Study Presented at ASCO

Paradigm Health today announced its role in the execution of a multicenter, hybrid, observational post-marketing commitment study in the United States evaluating an FDA-approved therapy in patients ...
Yahoo Finance

Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe ...
Seeking Alpha

Anteris Technologies Looks Bullish If DurAVR's PARADIGM Delivers

Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This ...
Morningstar

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower ...
Morningstar

EndoQuest Advances Multicenter PARADIGM Trial with Completion of Procedures at Baylor St. Luke’s Medical Center

Clinical progress expands to Baylor St. Luke’s with robotic endoscopic submucosal dissection procedures performed by Dr. Mohamed Othman and Dr. Tara Keihanian EndoQuest Robotics, Inc., a pioneering ...
Seeking Alpha

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass., July 9, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) (NASDAQ: NRSN) ("NeuroSense"), a late-clinical ...